Electra Therapeutics, Inc. (ETRA) Stock Price & Analysis
Electra Therapeutics, Inc. (ETRA) closed at USD 8.75 on Thursday, October 15, 2026, down 2.13% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.94; the Oct 15, 2026 session ranged USD 8.58–8.99 on volume of 179,559 shares. Market capitalization is $549.21M, with a 52-week range of USD 8.5–15.5 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ETRA.md
Key facts (ETRA)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 33.33 (range 32–36).
- Total return with dividends: 1Y -34.0% vs S&P 500 +18.1%; 5Y -34.0% vs S&P 500 +85.1%.
Analysts (ETRA)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 33.33 (low 32, high 36).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Jefferies | Initiated | Buy | $32 |
| 2026-10-13 | Evercore ISI Group | Initiated | Outperform | $36 |
| 2026-10-13 | TD Cowen | Initiated | Buy | |
| 2026-10-13 | Cantor Fitzgerald | Initiated | Overweight |
Total return (dividends reinvested) (ETRA)
| 1Y (from 2026-09-18) | 5Y (from 2026-09-14) | |
|---|---|---|
| Total return | -34.0% | -34.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 61.0% | 45.5% |
| Max drawdown | -38.1% (Sep 2026→Oct 2026) | -34.0% (Sep 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 8.75 |
|---|---|
| Change | ▼ 2.13% (down) |
| Previous Close | USD 8.94 |
| Open | USD 8.97 |
| Day Range | USD 8.58 – 8.99 |
| 52-Week Range | USD 8.5 – 15.5 |
| Volume | 179,559 shares |
| Market Cap | $549.21M |
| Exchange | NMS |
Technical Analysis (ETRA)
Nexqual's technical model rates ETRA "NEUTRAL" based on 2 bullish and 2 bearish signals across 20 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 20.09 (oversold) |
Analyst Ratings (ETRA)
Wall Street analysts rate ETRA "Buy" based on 4 analysts, with a mean price target of USD 33.33 (range USD 32–36), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 33.33 |
| High Target | USD 36 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ETRA)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (ETRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.02 |
| Current Ratio | 7.37 |
| Total Cash | $97.72M |
| Total Debt | $1.98M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (ETRA)
Nexqual rates Electra Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $98M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$75M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ETRA)
| Insider Ownership | +1.37% |
|---|---|
| Institutional Ownership | +25.73% |
| Shares Outstanding | 62.77M |
| Float | 29.12M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (ETRA)
Electra Therapeutics, Inc. is led by Quehuong Dong M.B.A., Pharm.D. (age 43), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | Quehuong Dong M.B.A., Pharm.D. (age 43) |
|---|---|
| Chief Technology Officer | Gary S. Koe (age 61) |
| Chief Financial Officer | Christopher William Clark C.F.A. (age 47) |
| Chief Scientific Officer | Graham Parry (age 61) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt